Abcuro snags $155 million to see ABC008 through pivotal inclusion body myositis study

17 Aug 2023
firstwordpharma.com
Phase 1ImmunotherapyINDADCCell Therapy
Abcuro on Thursday announced that it raised $155 million in Series B financing that will be used to complete a Phase II/III registrational trial of ABC008 for the treatment of inclusion body myositis (IBM). The investment was co-led by Redmile Group and Bain Capital Life Sciences, with other participants including RA Capital Management, Samsara BioCapital and Sanofi Ventures.
The anti-KLRG1 antibody ABC008 has been designed to treat diseases mediated by highly cytotoxic T-cells, including IBMIBM, T-cell large granular lymphocytic leukaemia (T-LGLL) and mature T-cell malignancies. The pivotal study in IBM, which began in April, aims to recruit around 230 patients and investigate the efficacy of ABC008 as measured by the IBM Functional Rating Scale (IBMFRS) at week 76.
"Targeting the depletion of cytotoxic T-cells that express KLRG1 with ABC008…has generated exciting early data in patients with IBM," remarked chief medical officer H. Jeffrey Wilkins. The company previously highlighted data from a Phase I trial showing that at the ABC008 dose levels being used in the Phase II/III study, 97% depletion of blood target cells was observed at 28 days post injection.
Abcuro is also evaluating the antibody in a Phase I/II trial for T-LGLL, while plans are under way for a Phase I/II study in T- and NK-cell lymphomas. Meanwhile, the company, which closed a $42 million Series A-1 financing in 2021, has a monoclonal antibody dubbed ABC015 in preclinical development. The therapy is designed to interrupt the interaction of KLRG1 with E- and N-cadherin on the surface of cancer cells.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.